Analytical goals for the determination of HbA2

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 5, 2013, Pages 937-941

  Mosca, Andrea ^a   Paleari, Renata ^a   Wild, Barbara ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UK NEQAS (H)   (United Kingdom)

Author keywords

Analytical goals; Biologic variation; Hemoglobin A2; Reference systems

Indexed keywords

HEMOGLOBIN A2;

BETA THALASSEMIA; BLOOD SAMPLING; HEMOGLOBIN DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY PERSONNEL; MEASUREMENT ERROR; MOTIVATION; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW;

ADULT; FEMALE; HEALTHY VOLUNTEERS; HEMOGLOBIN A2; HUMANS; MALE; MIDDLE AGED;

EID: 84882251462     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0575     Document Type: Review

References (15)

1. Mosca A, Paleari R, Ivaldi G, Galanello R, Giordano PC. The role of haemoglobin A 2 testing in the diagnosis of thalassaemias and related haemoglobinopathies. J Clin Pathol 2009;62:13-7.
2. Giambona A, Passarello C, Renda D, Maggio A. The significance of the hemoglobin A 2 value in screening for hemoglobinopathies. Clin Biochem 2009;42:1786-96.
3. Mosca A, Paleari R, Galanello R, Sollaino C, Perseu L, Demartis FR, et al. New analytical tools and epidemiological data for the identification of HbA 2 borderline subjects in the screening for beta-thalassemia. Bioelectrochemistry 2008;73:137-40.
4. Perseu L, Satta S, Moi P, Demartis FR, Manunza L, Sollaino MC, et al. KLF1 gene mutations cause borderline HbA 2 . Blood 2011;118:4454-8.
5. Stephens AD, Angastiniotis M, Baysal E, Chan V, Fucharon S, Giordano PC, et al, on behalf of the International Council for the Standardisation of Haematology (ICSH). ICSH recommendations for the measurement of haemoglobin A 2 . Int J Lab Hem 2012;34:1-13.
6. Batterbee H, De la Salle B, McTaggart P, Dor è C, Wild B, Hyde K. Evaluation of UK NEQAS (H) HbA 2 and related performance data. UK NEQAS (H) 2010 (Report).
7. Paleari R, Gulbis B, Cotton F, Mosca A. Interlaboratory comparison of current high-performance methods for HbA 2 . Int J Lab Hem 2012;34:362-8.
8. Klee GG. Establishment of outcome-related analytic performance goals. Clin Chem 2010;56:714-22.
9. Plebani M. Quality specifications: self pleasure for clinical laboratories or added value for patient management ? Clin Chem Lab Med 2007;45:462-6.
10. Paleari R, Montagnana M, Danese E, Tozzi M, Guidi GC, Mosca A. Determination of biological variation of hemoglobin A 2 . Biochim Clin 2011;35:458-60.
11. Braga F, Dolci A, Montagnana M, Pagani F, Paleari R, Guidi GC, et al. Revaluation of biological variation of glycated hemoglobin (HbA1c) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clin Chim Acta 2011;412:1412-6.
12. VI international symposium on haemoglobins. The new chapter. A Menarini Diagnostics symposium, Dublin 2 June 2012. Available from: www.thenewchapter.eu.
13. Old J, Traeger-Synodinos J, Christou S, Borg J, Molyneux A, Henderson S, et al. Normal HbA2 beta-thalassaemia in Europe-characterisation of eight mutations, including a novel PolyA mutation (-AA). 10th International Conference on Thalassaemia & Haemoglobinopathies, Singapore 2008.
14. Sickle cell and thalassaemia handbook for laboratories 2009. NHS sickle cell and thalassaemia screening programme. Available from: www.sct.screening. nhs.uk. Accessed September 2012.
15. Kaiser P, Akerboom T, Ohlendorf R, Reinauer H. Liquid chromatography- isotope dilution-mass spectrometry as a new basis for the reference measurement procedure for hemoglobin A1c determination. Clin Chem 2010;56:750-4.